Current choices of antibiotic treatment for Pseudomonas aeruginosa infections.
Anti-Bacterial Agents
/ therapeutic use
Antimicrobial Stewardship
/ methods
Cephalosporins
/ therapeutic use
Drug Resistance, Multiple, Bacterial
/ drug effects
Fluoroquinolones
/ therapeutic use
Humans
Phage Therapy
/ methods
Pseudomonas Infections
/ drug therapy
Pseudomonas aeruginosa
/ isolation & purification
beta-Lactamase Inhibitors
/ therapeutic use
beta-Lactams
/ therapeutic use
Cefiderocol
Journal
Current opinion in infectious diseases
ISSN: 1473-6527
Titre abrégé: Curr Opin Infect Dis
Pays: United States
ID NLM: 8809878
Informations de publication
Date de publication:
12 2020
12 2020
Historique:
entrez:
5
11
2020
pubmed:
6
11
2020
medline:
10
7
2021
Statut:
ppublish
Résumé
Pseudomonas aeruginosa is one of the most feared nosocomial pathogens. Treatment of P. aeruginosa infections is challenging because of the limited choices of antibiotics and the emergent resistance of the pathogen. The present review aims at addressing the management of P. aeruginosa infections and highlighting the novel antibiotics that show a future promising role. Novel fluoroquinolones have been recently introduced and show favorable activity. New combinations of β-lactams/β-lactamase inhibitors have been studied in various indications of infections because of P. aeruginosa. Cefiderocol, a new cephalosporin, shows very promising results against P. aeruginosa. Currently, combination therapy is only recommended in limited scenarios. Extended-infusion of β-lactams exhibit clinical benefit. Bacteriophage therapy is a growing field of interest and may have an impactful effect on the treatment of resistant P. aeruginosa. Factors that guide clinical decisions for empiric and directed P. aeruginosa therapy include the epidemiology, the patient's risk factors, the site of infection, and the available treatment options. Conventional antipseudomonal antibiotics have been used successfully for a long time, but the increase in worldwide resistance necessitates the need for newer agents. Antimicrobial stewardship is essential to preserve the new drugs and prevent future development of resistance.
Identifiants
pubmed: 33148986
doi: 10.1097/QCO.0000000000000677
pii: 00001432-202012000-00008
doi:
Substances chimiques
Anti-Bacterial Agents
0
Cephalosporins
0
Fluoroquinolones
0
beta-Lactamase Inhibitors
0
beta-Lactams
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
464-473Références
Crabtree TD, Gleason TG, Pruett TL, Sawyer RG. Trends in nosocomial pneumonia in surgical patients as we approach the 21st century: a prospective analysis. Am Surg 1999; 65 (8):706–709. discussion 710.
Resende MM, Monteiro SG, Callegari B, et al. Epidemiology and outcomes of ventilator-associated pneumonia in northern Brazil: an analytical descriptive prospective cohort study. BMC Infect Dis 2013; 13 (1):119.
Weiner LM, Webb AK, Limbago B, et al. Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014. Infect Control Hosp Epidemiol 2016; 37 (11):1288–1301.
Pang Z, Raudonis R, Glick BR, et al. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. Biotechnol Adv 2019; 37 (1):177–192.
Meletis G, Bagkeri M. Pseudomonas aeruginosa: multi-drug-resistance development and treatment options. Infect Control [Internet]; 2013. https://www.intechopen.com/books/infection-control/pseudomonas-aeruginosa-multi-drug-resistance-development-and-treatment-options. [Accessed 25 May 2020]
Aloush V, Navon-Venezia S, Seigman-Igra Y, et al. Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact. Antimicrob Agents Chemother 2006; 50 (1):43–48.
Nakamura A, Miyake K, Misawa S, et al. Meropenem as predictive risk factor for isolation of multidrug-resistant Pseudomonas aeruginosa. J Hosp Infect 2013; 83 (2):153–155.
Tartof SY, Kuntz JL, Chen LH, et al. Development and assessment of risk scores for carbapenem and extensive β-lactam resistance among adult hospitalized patients with pseudomonas aeruginosa infection. JAMA Netw Open [Internet]; 2018;1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324445/
Bassetti M, Carnelutti A, Peghin M. Patient specific risk stratification for antimicrobial resistance and possible treatment strategies in gram-negative bacterial infections. Expert Rev Anti Infect Ther 2017; 15 (1):55–65.
Micek ST, Lloyd AE, Ritchie DJ, et al. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005; 49 (4):1306–1311.
Jabbour J-F, Sharara SL, Kanj SS. Treatment of multidrug-resistant Gram-negative skin and soft tissue infections. Curr Opin Infect Dis 2020; 33 (2):146–154.
Pugh R, Grant C, Cooke RPD, Dempsey G. Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults. Cochrane Database Syst Rev 2015; 00 (8):CD007577.
Pillar CM, Torres MK, Brown NP, et al. In vitro activity of doripenem, a carbapenem for the treatment of challenging infections caused by gram-negative bacteria, against recent clinical isolates from the United States. Antimicrob Agents Chemother 2008; 52 (12):4388–4399.
Morrissey I, Hackel M, Badal R, et al. A review of ten years of the study for monitoring antimicrobial resistance trends (SMART) from 2002 to 2011. Pharmaceuticals 2013; 6 (11):1335–1346.
Rosenthal VD, Al-Abdely HM, El-Kholy AA, et al. International Nosocomial Infection Control Consortium report, data summary of 50 countries for 2010–2015: device-associated module. Am J Infect Control 2016; 44 (12):1495–1504.
Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999; 43 (6):1379–1382.
McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008; 178 (9):921–928.
Kirkby S, Novak K, McCoy K. Aztreonam (for inhalation solution) for the treatment of chronic lung infections in patients with cystic fibrosis: an evidence-based review. Core Evid 2011; 6:59–66.
Jorth P, McLean K, Ratjen A, et al. Evolved Aztreonam Resistance Is Multifactorial and Can Produce Hypervirulence in Pseudomonas aeruginosa. mBio [Internet]. 2017 Nov 8 [cited 2020 May 26];8(5). Available from: https://mbio.asm.org/content/8/5/e00517-17
Köhler T, Michea-Hamzehpour M, Plesiat P, et al. Differential selection of multidrug efflux systems by quinolones in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1997; 41 (11):2540–2543.
Stubbings W, Leow P, Yong GC, et al. In vitro spectrum of activity of finafloxacin, a novel, pH-activated fluoroquinolone, under standard and acidic conditions▿. Antimicrob Agents Chemother 2011; 55 (9):4394–4397.
Tulkens PM, Van Bambeke F, Zinner SH. Profile of a novel anionic fluoroquinolone—delafloxacin. Clin Infect Dis Off Publ Infect Dis Soc Am 2019; 68: (Suppl 3): S213–S222.
McKeage K. Finafloxacin: first global approval. Drugs 2015; 75 (6):687–693.
Wagenlehner F, Nowicki M, Bentley C, et al. Explorative randomized phase II clinical study of the efficacy and safety of finafloxacin versus ciprofloxacin for treatment of complicated urinary tract infections. Antimicrob Agents Chemother [Internet]. 2018;62(4). https://aac.asm.org/content/62/4/e02317-17
Ocheretyaner ER, Park TE. Delafloxacin: a novel fluoroquinolone with activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. Expert Rev Anti Infect Ther 2018; 16 (7):523–530.
Lahiri T, Hempstead SE, Brady C, et al. Clinical practice guidelines from the cystic fibrosis foundation for preschoolers with cystic fibrosis. Pediatrics 2016; 137:e20151784.
Dhand R. The rationale and evidence for use of inhaled antibiotics to control pseudomonas aeruginosa infection in non-cystic fibrosis bronchiectasis. J Aerosol Med Pulm Drug Deliv 2018; 31 (3):121–138.
Zhanel GG, Lawson CD, Zelenitsky S, et al. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Rev Anti Infect Ther 2012; 10 (4):459–473.
Shaeer KM, Zmarlicka MT, Chahine EB, et al. Plazomicin: a next-generation aminoglycoside. Pharmacother J Hum Pharmacol Drug Ther 2019; 39 (1):77–93.
Florescu DF, Qiu F, McCartan MA, et al. What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis 2012; 54 (5):670–680.
Imberti R, Cusato M, Villani P, et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration. Chest 2010; 138 (6):1333–1339.
Boisson M, Jacobs M, Grégoire N, et al. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients. Antimicrob Agents Chemother 2014; 58 (12):7331–7339.
Peña C, Suarez C, Ocampo-Sosa A, et al. Effect of adequate single-drug vs combination antimicrobial therapy on mortality in Pseudomonas aeruginosa bloodstream infections: a post Hoc analysis of a prospective cohort. Clin Infect Dis 2013; 57 (2):208–216.
Gallagher JC, Satlin MJ, Elabor A, et al. Ceftolozane-Tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: a multicenter study. Open Forum Infect Dis [Internet]. 2018;5(11). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247659/
Sader HS, Flamm RK, Carvalhaes CG, Castanheira M. Antimicrobial susceptibility of Pseudomonas aeruginosa to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by U.S. Census Divisions: Results from the 2017 INFORM Program. Antimicrob Agents Chemother [Internet]. 2018;62(12). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6256773/
United States Food and Drug Administration. FDA approves new treatment for hospital-acquired and ventilator-associated bacterial pneumonia FDA.gov [Internet]. USA: FDA. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-hospital-acquired-and-ventilator-associated-bacterial-pneumonia [3 June 2019; 2 June 2020]
Wi YM, Greenwood-Quaintance KE, Schuetz AN, et al. Activity of Ceftolozane-Tazobactam against Carbapenem-resistant, non-Carbapenemase-producing pseudomonas aeruginosa and associated resistance mechanisms. Antimicrob Agents Chemother 2018; 62 (1):00.
Haidar G, Philips NJ, Shields RK, et al. Ceftolozane-Tazobactam for the treatment of multidrug-resistant pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance. Clin Infect Dis 2017; 65 (1):110–120.
Cho JC, Fiorenza MA, Estrada SJ. Ceftolozane/Tazobactam: a novel Cephalosporin/β-Lactamase inhibitor combination. Pharmacotherapy 2015; 35 (7):701–715.
Nichols WW, de Jonge BLM, Kazmierczak KM, et al. In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to ceftazidime-avibactam (INFORM 2012 to 2014). Antimicrob Agents Chemother 2016; 60 (8):4743–4749.
Carmeli Y, Armstrong J, Laud PJ, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis 2016; 16 (6):661–673.
Lob SH, Karlowsky JA, Young K, et al. Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015-17. J Antimicrob Chemother 2019; 74 (8):2284–2288.
Zhanel GG, Lawrence CK, Adam H, et al. Imipenem-Relebactam and Meropenem-Vaborbactam: two novel Carbapenem-β-Lactamase inhibitor combinations. Drugs 2018; 78 (1):65–98.
Carvalhaes CG, Shortridge D, Sader HS, Castanheira M. Activity of meropenem-vaborbactam against bacterial isolates causing pneumonia in hospitalized patients from U.S. Hospitals during 2014 to 2018. Antimicrob Agents Chemother [Internet] 2020. https://aac.asm.org/content/early/2020/01/02/AAC.02177-19
Portsmouth S, van Veenhuyzen D, Echols R, et al. Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis 2018; 18 (12):1319–1328.
Hsueh SC, Lee YJ, Huang YT, et al. In vitro activities of cefiderocol, ceftolozane/tazobactam, ceftazidime/avibactam and other comparative drugs against imipenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii, and Stenotrophomonas maltophilia, all associated with bloodstream infections in Taiwan. J Antimicrob Chemother 2019; 74 (2):380–386.
Grabein B, Graninger W, Rodríguez Baño J, et al. Intravenous fosfomycin—back to the future. Systematic review and meta-analysis of the clinical literature. Clin Microbiol Infect 2017; 23 (6):363–372.
Samonis G, Maraki S, Karageorgopoulos DE, et al. Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur J Clin Microbiol Infect Dis 2012; 31 (5):695–701.
Asuphon O, Montakantikul P, Houngsaitong J, et al. Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation. Int J Infect Dis 2016; 50:23–29.
Trapnell BC, McColley SA, Kissner DG, et al. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. Am J Respir Crit Care Med 2012; 185 (2):171–178.
Sader HS, Flamm RK, Dale GE, et al. Murepavadin activity tested against contemporary (2016-17) clinical isolates of XDR Pseudomonas aeruginosa. J Antimicrob Chemother 2018; 73 (9):2400–2404.
Tümmler B. Emerging therapies against infections with Pseudomonas aeruginosa. F1000Research [Internet]. 2019;8. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6688719/
Paulsson M, Granrot A, Ahl J, et al. Antimicrobial combination treatment including ciprofloxacin decreased the mortality rate of Pseudomonas aeruginosa bacteraemia: a retrospective cohort study. Eur J Clin Microbiol Infect Dis 2017; 36 (7):1187–1196.
Paul M, Leibovici L. Editorial commentary: combination therapy for Pseudomonas aeruginosa bacteremia: where do we stand? Clin Infect Dis 2013; 57:217–220.
Paul M, Lador A, Grozinsky-Glasberg S, Leibovici L. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2014; 1:CD003344.
Lodise TP, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007; 44 (3):357–363.
Bauer KA, West JE, O’Brien JM, Goff DA. Extended-infusion cefepime reduces mortality in patients with Pseudomonas aeruginosa infections. Antimicrob Agents Chemother 2013; 57 (7):2907–2912.
Louie A, Bied A, Fregeau C, et al. Impact of different carbapenems and regimens of administration on resistance emergence for three isogenic pseudomonas aeruginosa strains with differing mechanisms of resistance. Antimicrob Agents Chemother 2010; 54 (6):2638–2645.
Bulik CC, Christensen H, Li P, et al. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2010; 54 (2):804–810.
Pires DP, Vilas Boas D, Sillankorva S, Azeredo J. Phage therapy: a step forward in the treatment of Pseudomonas aeruginosa infections. J Virol 2015; 89 (15):7449–7456.
Wright A, Hawkins CH, Anggård EE, Harper DR. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol 2009; 34 (4):349–357.
Chan BK, Turner PE, Kim S, Mojibian HR, et al. Phage treatment of an aortic graft infected with Pseudomonas aeruginosa. Evol Med Public Health 2018; 2018 (1):60–66.
Aslam S, Courtwright AM, Koval C, et al. Early clinical experience of bacteriophage therapy in 3 lung transplant recipients. Am J Transplant 2019; 19 (9):2631–2639.
Liu L, Liu B, Li Y, Zhang W. Successful control of resistance in Pseudomonas aeruginosa using antibiotic stewardship and infection control programs at a Chinese university hospital: a 6-year prospective study. Infect Drug Resist 2018; 11:637–646.
Pakyz AL, Oinonen M, Polk RE. Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother 2009; 53 (5):1983–1986.
Stultz JS, Arnold SR, Shelton CM, et al. Antimicrobial stewardship impact on Pseudomonas aeruginosa susceptibility to meropenem at a tertiary pediatric institution. Am J Infect Control 2019; 47 (12):1513–1515.